Download Free Drug Device Selection In Heart Failure Book in PDF and EPUB Free Download. You can read online Drug Device Selection In Heart Failure and write the review.

Provides review of the most recent advances in drugs and devices used for the treatment of heart failure, helping clinicians select the best evidence-based therapy for patients. Written by experienced cardiologists from San Francisco and Philadelphia.
Heart failure affects over 5 million patients in the United States alone, and is a chronic and debilitating disease. While a number of pharmacologic therapies have shown varying degrees of effectiveness, many recent advances in the treatment of heart failure has focused on device based therapies. In Device Therapy in Heart Failure, William H. Maisel and a panel of authorities on the use and implementation of device based therapies provide a comprehensive overview of the current and developing technologies that are used to treat heart failure. Individual chapters provide an in-depth analysis of devices such as CRT’s and ICD’s, while broader topics such as the pathophysiology of heart failure and its current medical therapies are also discussed. Additional topics include Pacing and Defibrillation for Atrial Arrhythmias, Atrial Fibrillation Ablation, and Percutaneous Treatment of Coronary Artery Disease.
For many years, there has been a great deal of work done on chronic congestive heart failure while acute heart failure has been considered a difficult to handle and hopeless syndrome. However, in recent years acute heart failure has become a growing area of study and this is the first book to cover extensively the diagnosis and management of this complex condition. The book reflects the considerable amounts of new data reported and many new concepts which have been proposed in the last 3-4 years looking at the epidemiology, diagnostic and treatment of acute heart failure.
This book systematically focuses on central sleep apneas, analyzing their relationship especially with heart failure and discussing recent research results and emerging treatment strategies based on feedback modulation. The opening chapters present historical background information on Cheyne-Stokes respiration (CSR), clarify terminology, and explain the mechanics and chemistry of respiration. Following a description of the physiology of respiration, the pathophysiology underlying central apneas in different disorders and particularly in heart failure is discussed. The similarities and differences of obstructive and central apneas are then considered. The book looks beyond the concept of sleep apnea to daytime CSR and periodic breathing during effort and contrasts the opposing views of CSR as a compensatory phenomenon or as detrimental to the failing heart. The diagnostic tools currently in use for the detection of CSR are thoroughly reviewed, with guidance on interpretation of findings. The book concludes by describing the various forms of treatment that are available for CSR and by explaining how to select patients for treatment.
This new title in the American Heart Association Clinical Series offers an up-to-date overview of the causes and damage related to dyssynchronopathy - a new pathophysiological entity related to spontaneous or pacing-induced mechanical abnormalities which causes heart failure. It presents the most recent diagnostic non-invasive tools and provides simple, practice-oriented therapeutic proposals for heart failure patients.
Heart failure is defined as reduced ability of the heart to pump blood and maintain normal bodily function. Heart transplantation is currently the preferred treatment for end-stage heart failure but the supply of donor hearts is insufficient to meet the need and many patients are not eligible for transplantation due to age or comorbid conditions. Implantable mechanical pumps can assist the circulation of blood by the ventricles. Left ventricular assist devices (LVADs) have been approved by the U.S. Food and Drug Administration (FDA) for use in patients awaiting transplant (a bridge to transplant) and as a last resort in patients with refractory heart failure who are not eligible for a heart transplant (destination therapy). In January 2010, the first newer generation, rotary continuous flow ventricular assist device (HeartMate II) was approved by the FDA for destination therapy. Eligibility criteria are essentially the same as those used to select patients for the pivotal clinical trial that included patients with shortness of breath and/or fatigue at rest or during minimal exertion despite treatment with optimal therapy for heart failure associated with a low ejection fraction (
Cardiovascular, respiratory, and related conditions cause more than 40 percent of all deaths globally, and their substantial burden is rising, particularly in low- and middle-income countries (LMICs). Their burden extends well beyond health effects to include significant economic and societal consequences. Most of these conditions are related, share risk factors, and have common control measures at the clinical, population, and policy levels. Lives can be extended and improved when these diseases are prevented, detected, and managed. This volume summarizes current knowledge and presents evidence-based interventions that are effective, cost-effective, and scalable in LMICs.
Now there is an up-to-date guide for optimizing pharmacologic therapy in treating patients with heart failure. Reflecting current practice at leading medical centers, Heart Failure: Pharmacologic Management provides both the biologic and pathologic underpinnings of each pharmacologic agent in current use. It also supplies detailed discussions of the clinical investigations that support current understanding of the risks and benefits associated with the use of these drugs. Thorough references make the book useful to the novice as well as the experienced clinician. Initial chapters focus on agents that are considered standard care: diuretics ACE inhibitors angiotensin receptor antagonists aldosterone antagonists beta-blockers The discussion moves to agents currently under investigation: Vasopressin antagonists erythropoietin Next, the authors consider some controversial drugs: inotropic agents antiarrhythmic drugs anticoagulants An insightful examination of pharmacogenetics considers: how studies of the genetic profile of patients helps determine which patient populations are most likely to respond to a given class of drugs the potential use of pharmacogenetics to tailor a pharmacologic regimen for maximum benefit and minimum risk Multidrug pharmacy for heart failure therapy An extremely helpful concluding chapter provides a roadmap of drugs with which to approach the patient with heart failure, along with an overview of the skills you need to use it most effectively. This straightforward, step-by-step algorithm will save you countless hours of research and help you make your prescribing decisions with confidence.
This issue of Heart Failure Clinics, guest edited by Drs. Giuseppe Pacileo, Daniele Masarone, Francesco Grigioni and Luciano Potena, will cover key topics in Advanced Heart Failure: From Pathophysiology to Clinical Management. This issue is one of four issues selected each year by our series consulting editor, Dr. Eduardo Bossone. Topics discussed in this issue include (but are not limited to): Pathophysiology of advanced heart failure: what I need to know for clinical management?, Advanced heart failure: definition, epidemiology and clinical course, Echocardiography in advanced heart failure: beyond diagnosis, Disease modifier drugs in patients with advanced heart failure: How to optimize their use?, Congestion in patients with advanced heart failure: Assessment and treatment, Inotropes in patients with advanced heart failure: Not only palliative care, Cardiac resynchronization therapy and cardiac contractility modulation in patients with advanced heart failure: How to select the right candidate?, Mitral and tricuspid valves percutaneous repair in patients with advanced heart failure: Panacea, or Pandora's box?, Left ventricular assist device: Indication, timing and management, Listing criteria for heart transplant: Role of cardiopulmonary exercise test and of prognostic scores, Right heart catheterization in patients with advanced heart failure: when to perform, how to interpreter?, Advanced heart failure in special population: Cardiomyopathies, Advanced heart failure in special population: Pediatric age, Advanced heart failure in special population: Heart failure with preserved ejection fraction and Treatment of advanced heart failure: What future holds?. Provides in-depth, clinical reviews on advanced heart failure, providing actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field; Authors synthesize and distill the latest research and practice guidelines to create these timely topic-based reviews.